CUREVAC N.V. overview

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1...

Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update 12.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST. Dial-in numbers to...

Issuer: CureVac / Key word(s): Quarter Results CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 07.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 TÜBINGEN, Germany/BOSTON, USA – November 7, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global...

Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024. Mr. Malkomes joins CureVac at a pivotal...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12 th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024. More detailed preliminary safety, tolerability...

Issuer: CureVac / Key word(s): Personnel CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer 04.11.2024 / 13:03 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer Experienced CFO and investment banker with 30-year track record will help drive CureVac’s...

Issuer: CureVac / Key word(s): Conference CureVac to Present at the 12th International mRNA Health Conference 04.11.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Present at the 12th International mRNA Health Conference TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid...